147 results about "Choroidal neovascularization" patented technology

The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.

RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

The invention discloses a spectral-domain optical coherence tomography (SD-OCT) retina image choroidal neovascularization (CNV) segmentation method based on concavity and convexity, and belongs to the technical field of image processing. The method comprises the following steps: first, estimating the retina and choroid area of an input SD-OCT image, and positioning the internal limiting membrane (ILM) and the choroid-sclera junction (CSJ); then, estimating the retina pigment epithelium (RPE) layer according to the gradual change feature of the reflectivity of the retina image, and estimating the Bruch's membrane (BM) layer based on the concavity and convexity of the RPE layer; and finally, estimating a preliminary CNV region according to the thickness difference between the RPE layer and the BM layer, and correcting the upper border of CNV to get a final CNV segmentation result. The experimental results show that the algorithm proposed in the invention can be used to segment CNV robustly and precisely, and is of great significance to facilitating subsequent CNV quantitative analysis and improving the work efficiency of doctors.

The invention discloses a partitioning algorithm for choroidal neovascularization in an OCT image. The algorithm includes steps of S01, designing a structure prior learning method for a training image and constructing a structure prior matrix used for distinguishing a choroidal neovascularization zone and a background zone; S02, converting the OCT original image to a saliency enhancing image used for enhancing the saliency of the choroidal neovascularization zone based on the structure prior matrix; S03, adopting multi-scale analysis on the saliency enhancing image and dividing the saliency enhancing image into m scales; S04, acquiring m trained convolutionneural network model based on each scale training; S05, processing a testing image by utilizing the step S01, S02, S03 and performing testing by utilizing the trained convolutionneural network model in the step S04, outputting m portioning results and fusing the m partitioning results into the final partitioning result. By adopting the algorithm provided by the invention, the precision of partitioning of the choroidal neovascularization in the OCT image can be improved distinctively.

The present invention relates to oxygenated ophthalmic topical compositions and methods of administering oxygenated ophthalmic topical compositions. The present invention also encompasses methods for making and administering the oxygenated ophthalmic topical compositions for use in treating or ameliorating pathologic conditions, complications, diseases and symptoms related to hypoxia of the anterior eye structure, including corneal neovascularization (CNV), edema, abrasions, infections, infiltrates, dry eye syndrome, contact lens intolerance; and redness, blurred vision, discomfort, foreign body sensation, photophobia, and irritation.

Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ ID NO: 3 and SEQ ID NO: 4 suppressed spermidine-induced retinal pigment epithelial damage, tunicamycin-induced photoreceptor cell damage, and laser-induced choroidal neovascularization. Thus, the JNK-inhibitory peptide of the present invention is useful for prophylaxis or therapy of a retinal disease. By the use of this JNK-inhibitory peptide, a drug and a method are provided which are capable of preventing or treating a retinal disease even by topical administration to the eye, and use of the JKN-inhibitory peptide for manufacturing the drug is also provided.

The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization.

Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.

The invention includes processes mainly for the treatment of angiogenic diseases, such as diabetic retinopathy, arthritis, cancer, psoriasis, Kaposi's sarcoma, hemangiomas, myocardial angiogenesis, atherosclerosis, and ocular angiogenic diseases such as choroidal neovascularization, retinopathy of prematurity (retrolental fibroplasias), macular degeneration, corneal graft rejection, rubeosis, neuroscular glacoma and Oster Webber syndrome. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.